These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29199201)

  • 21. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
    Mori Y; Taniguchi Y; Matsuura K; Sezaki K; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2011 Jul; 13(7):699-703. PubMed ID: 21504334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
    Liu X; Men P; Wang Y; Zhai S; Liu G
    Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postprandial Hyperlipidemia and Remnant Lipoproteins.
    Masuda D; Yamashita S
    J Atheroscler Thromb; 2017 Feb; 24(2):95-109. PubMed ID: 27829582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sitagliptin for Type 2 diabetes: a 2015 update.
    Lee M; Rhee MK
    Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):597-610. PubMed ID: 26000559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials.
    Fan M; Li Y; Zhang S
    Medicine (Baltimore); 2016 Jan; 95(2):e2386. PubMed ID: 26765417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
    van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
    Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
    Marques C; Gonçalves A; Pereira PMR; Almeida D; Martins B; Fontes-Ribeiro C; Reis F; Fernandes R
    Life Sci; 2019 Oct; 234():116738. PubMed ID: 31398418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study.
    Nozue T; Fukui K; Koyama Y; Fujii H; Kunishima T; Hikita H; Hibi K; Miyazawa A; Michishita I
    Heart Vessels; 2016 May; 31(5):649-54. PubMed ID: 25794984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Li D; Shi W; Wang T; Tang H
    Diabetes Obes Metab; 2018 Aug; 20(8):1972-1976. PubMed ID: 29573110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
    Göke R; Eschenbach P; Dütting ED
    Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34⁺CXCR4⁺ cells in patients with type 2 diabetes.
    Aso Y; Jojima T; Iijima T; Suzuki K; Terasawa T; Fukushima M; Momobayashi A; Hara K; Takebayashi K; Kasai K; Inukai T
    Endocrine; 2015 Dec; 50(3):659-64. PubMed ID: 26209038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAÏVE SUBJECTS WITH TYPE 2 DIABETES.
    Kutoh E; Wada A; Hayashi J
    Endocr Pract; 2018 Dec; 24(12):1063-1072. PubMed ID: 30289315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
    Kurozumi A; Okada Y; Sugai K; Torimoto K; Tanaka Y
    J UOEH; 2018; 40(1):1-9. PubMed ID: 29553070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Widlansky ME; Puppala VK; Suboc TM; Malik M; Branum A; Signorelli K; Wang J; Ying R; Tanner MJ; Tyagi S
    Vasc Med; 2017 Jun; 22(3):189-196. PubMed ID: 28145158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery.
    Cardona S; Tsegka K; Pasquel FJ; Fayfman M; Peng L; Jacobs S; Vellanki P; Halkos M; Guyton RA; Thourani VH; Galindo RJ; Umpierrez G
    BMJ Open Diabetes Res Care; 2019; 7(1):e000703. PubMed ID: 31543976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.
    Ishikawa S; Shimano M; Watarai M; Koyasu M; Uchikawa T; Ishii H; Inden Y; Takemoto K; Murohara T
    Am J Cardiol; 2014 Aug; 114(3):384-8. PubMed ID: 24929624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
    Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
    Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.
    Underland LJ; Ilkowitz JT; Katikaneni R; Dowd A; Heptulla RA
    J Diabetes Sci Technol; 2017 May; 11(3):602-610. PubMed ID: 28349708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.
    Aso Y; Fukushima M; Sagara M; Jojima T; Iijima T; Suzuki K; Momobayashi A; Kasai K; Inukai T
    Diabetes Res Clin Pract; 2015 Dec; 110(3):250-6. PubMed ID: 26508675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.